Account
Insider Insights
09.02.2023
New criteria for ATMPs which must follow quality r...

The Federal Joint Committee (G-BA) has set out criteria for ATMPs which are likely to require qualit...

Read more
Insider Insights
08.02.2023
First Adalimumab Biosimilar Launch in the USA

The first adalimumab (branded Humira) biosimilar, Amjevita, has been launched in the US by pharmaceu...

Read more
Insider Insights
02.02.2023
NICE has recommended Yescarta as the first CAR T-c...

NICE has recommended the first CAR T-cell therapy, Yescarta for the treatment of some lymphomas in a...

Read more
Insider Insights
01.02.2023
Price cuts for generics could exacerbate ongoing p...

The economic committee for health products (CEPs) have announced a price reduction of €67 that wil...

Read more
Insider Insights
25.01.2023
UK to introduce first-of-its-kind framework to aid...

MHRA announces UK will introduce new framework aimed at making the manufacture of innovative medicin...

Read more
Insider Insights
25.01.2023
AstraZeneca/Daiichi Sankyo’s Enhertu has been re...

NICE have recommended Enhertu for the treatment of HER2-positive breast cancer within a managed acce...

Read more
Insider Insights
25.01.2023
Singapore’s first global drug is being devel...

In a phase 3 study, Crovalimab was found to be efficacious and well tolerated in people with paroxys...

Read more
Insider Insights
25.01.2023
Biopharmas continue to offer hefty discounts to se...

Biopharmas offer significant discounts on their products in China, to try and score spots on the cou...

Read more
Insider Insights
24.01.2023
Takeda ready to file for TAK-755 enzyme replacemen...

Japan’s largest drugmaker Takeda says it aims to seek marketing authorisation for its TAK-755 enzy...

Read more
Insider Insights
23.01.2023
Germany – European joint assessment at deadlock ...

Germany's BPI and vfa advise that the implementation of the European Health Technology Assessment (E...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.